Global Peptide Cancer Vaccine Market Size, Manufacturers, Opportunities and Forecast to 2030
Summary
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
According to APO Research, The global Peptide Cancer Vaccine market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine.
The Peptide Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
According to APO Research, The global Peptide Cancer Vaccine market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine.
The Peptide Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Boston Biomedical
- Ultimovacs
- BrightPath Biotherapeutics
- TapImmune
- Immatics
- Sellas
- Imugene
- VAXON Biotech
- Generex Biotechnology
- ISA Pharmaceuticals
- OncoTherapy Science
- ITK-1
- GRN-1201
- TPIV200
- TPIV110
- UV1
- Galinpepimut-S
- TARP 27-35
- HER-Vaxx
- Vx-001
- Others
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts (2019-2030)
1.2.2 Global Peptide Cancer Vaccine Sales Estimates and Forecasts (2019-2030)
1.3 Peptide Cancer Vaccine Market by Pipeline
1.3.1 ITK-1
1.3.2 GRN-1201
1.3.3 TPIV200
1.3.4 TPIV110
1.3.5 UV1
1.3.6 Galinpepimut-S
1.3.7 TARP 27-35
1.3.8 HER-Vaxx
1.3.9 Vx-001
1.3.10 Others
1.4 Global Peptide Cancer Vaccine Market Size by Pipeline
1.4.1 Global Peptide Cancer Vaccine Market Size Overview by Pipeline (2019-2030)
1.4.2 Global Peptide Cancer Vaccine Historic Market Size Review by Pipeline (2019-2024)
1.4.3 Global Peptide Cancer Vaccine Forecasted Market Size by Pipeline (2025-2030)
1.5 Key Regions Market Size by Type
1.5.1 North America Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.2 Europe Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.3 Asia-Pacific Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.4 Latin America Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.5 Middle East and Africa Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
2 GLOBAL MARKET DYNAMICS
2.1 Peptide Cancer Vaccine Industry Trends
2.2 Peptide Cancer Vaccine Industry Drivers
2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
2.4 Peptide Cancer Vaccine Industry Restraints
3 MARKET COMPETITIVE LANDSCAPE BY COMPANY
3.1 Global Top Players by Peptide Cancer Vaccine Revenue (2019-2024)
3.2 Global Top Players by Peptide Cancer Vaccine Sales (2019-2024)
3.3 Global Top Players by Peptide Cancer Vaccine Price (2019-2024)
3.4 Global Peptide Cancer Vaccine Industry Company Ranking, 2022 VS 2023 VS 2024
3.5 Global Peptide Cancer Vaccine Key Company Manufacturing Sites & Headquarters
3.6 Global Peptide Cancer Vaccine Company, Product Type & Application
3.7 Global Peptide Cancer Vaccine Company Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023
3.8.3 2023 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier
4 PEPTIDE CANCER VACCINE REGIONAL STATUS AND OUTLOOK
4.1 Global Peptide Cancer Vaccine Market Size and CAGR by Region: 2019 VS 2023 VS 2030
4.2 Global Peptide Cancer Vaccine Historic Market Size by Region
4.2.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2019-2024)
4.2.2 Global Peptide Cancer Vaccine Sales in Value by Region (2019-2024)
4.2.3 Global Peptide Cancer Vaccine Sales (Volume & Value), Price and Gross Margin (2019-2024)
4.3 Global Peptide Cancer Vaccine Forecasted Market Size by Region
4.3.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2025-2030)
4.3.2 Global Peptide Cancer Vaccine Sales in Value by Region (2025-2030)
4.3.3 Global Peptide Cancer Vaccine Sales (Volume & Value), Price and Gross Margin (2025-2030)
5 PEPTIDE CANCER VACCINE BY APPLICATION
5.1 Peptide Cancer Vaccine Market by Application
5.1.1 Breast Cancer
5.1.2 Lung Cancer
5.1.3 Melanoma
5.1.4 Prostate Cancer
5.1.5 Others
5.2 Global Peptide Cancer Vaccine Market Size by Application
5.2.1 Global Peptide Cancer Vaccine Market Size Overview by Application (2019-2030)
5.2.2 Global Peptide Cancer Vaccine Historic Market Size Review by Application (2019-2024)
5.2.3 Global Peptide Cancer Vaccine Forecasted Market Size by Application (2025-2030)
5.3 Key Regions Market Size by Application
5.3.1 North America Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.2 Europe Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.3 Asia-Pacific Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.4 Latin America Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.5 Middle East and Africa Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
6 COMPANY PROFILES
6.1 Boston Biomedical
6.1.1 Boston Biomedical Comapny Information
6.1.2 Boston Biomedical Business Overview
6.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
6.1.5 Boston Biomedical Recent Developments
6.2 Ultimovacs
6.2.1 Ultimovacs Comapny Information
6.2.2 Ultimovacs Business Overview
6.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
6.2.5 Ultimovacs Recent Developments
6.3 BrightPath Biotherapeutics
6.3.1 BrightPath Biotherapeutics Comapny Information
6.3.2 BrightPath Biotherapeutics Business Overview
6.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
6.3.5 BrightPath Biotherapeutics Recent Developments
6.4 TapImmune
6.4.1 TapImmune Comapny Information
6.4.2 TapImmune Business Overview
6.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
6.4.5 TapImmune Recent Developments
6.5 Immatics
6.5.1 Immatics Comapny Information
6.5.2 Immatics Business Overview
6.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
6.5.5 Immatics Recent Developments
6.6 Sellas
6.6.1 Sellas Comapny Information
6.6.2 Sellas Business Overview
6.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
6.6.5 Sellas Recent Developments
6.7 Imugene
6.7.1 Imugene Comapny Information
6.7.2 Imugene Business Overview
6.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
6.7.5 Imugene Recent Developments
6.8 VAXON Biotech
6.8.1 VAXON Biotech Comapny Information
6.8.2 VAXON Biotech Business Overview
6.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
6.8.5 VAXON Biotech Recent Developments
6.9 Generex Biotechnology
6.9.1 Generex Biotechnology Comapny Information
6.9.2 Generex Biotechnology Business Overview
6.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
6.9.5 Generex Biotechnology Recent Developments
6.10 ISA Pharmaceuticals
6.10.1 ISA Pharmaceuticals Comapny Information
6.10.2 ISA Pharmaceuticals Business Overview
6.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
6.10.5 ISA Pharmaceuticals Recent Developments
6.11 OncoTherapy Science
6.11.1 OncoTherapy Science Comapny Information
6.11.2 OncoTherapy Science Business Overview
6.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
6.11.5 OncoTherapy Science Recent Developments
7 NORTH AMERICA BY COUNTRY
7.1 North America Peptide Cancer Vaccine Sales by Country
7.1.1 North America Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.1.2 North America Peptide Cancer Vaccine Sales by Country (2019-2024)
7.1.3 North America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
7.2 North America Peptide Cancer Vaccine Market Size by Country
7.2.1 North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2.2 North America Peptide Cancer Vaccine Market Size by Country (2019-2024)
7.2.3 North America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
8 EUROPE BY COUNTRY
8.1 Europe Peptide Cancer Vaccine Sales by Country
8.1.1 Europe Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.1.2 Europe Peptide Cancer Vaccine Sales by Country (2019-2024)
8.1.3 Europe Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
8.2 Europe Peptide Cancer Vaccine Market Size by Country
8.2.1 Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2.2 Europe Peptide Cancer Vaccine Market Size by Country (2019-2024)
8.2.3 Europe Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
9 ASIA-PACIFIC BY COUNTRY
9.1 Asia-Pacific Peptide Cancer Vaccine Sales by Country
9.1.1 Asia-Pacific Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.1.2 Asia-Pacific Peptide Cancer Vaccine Sales by Country (2019-2024)
9.1.3 Asia-Pacific Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
9.2 Asia-Pacific Peptide Cancer Vaccine Market Size by Country
9.2.1 Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2.2 Asia-Pacific Peptide Cancer Vaccine Market Size by Country (2019-2024)
9.2.3 Asia-Pacific Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
10 LATIN AMERICA BY COUNTRY
10.1 Latin America Peptide Cancer Vaccine Sales by Country
10.1.1 Latin America Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.1.2 Latin America Peptide Cancer Vaccine Sales by Country (2019-2024)
10.1.3 Latin America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
10.2 Latin America Peptide Cancer Vaccine Market Size by Country
10.2.1 Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2.2 Latin America Peptide Cancer Vaccine Market Size by Country (2019-2024)
10.2.3 Latin America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
11 MIDDLE EAST AND AFRICA BY COUNTRY
11.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country
11.1.1 Middle East and Africa Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.1.2 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2019-2024)
11.1.3 Middle East and Africa Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
11.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Country
11.2.1 Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Country (2019-2024)
11.2.3 Middle East and Africa Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
12 VALUE CHAIN AND SALES CHANNELS ANALYSIS
12.1 Peptide Cancer Vaccine Value Chain Analysis
12.1.1 Peptide Cancer Vaccine Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Peptide Cancer Vaccine Production Mode & Process
12.2 Peptide Cancer Vaccine Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Peptide Cancer Vaccine Distributors
12.2.3 Peptide Cancer Vaccine Customers
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts (2019-2030)
1.2.2 Global Peptide Cancer Vaccine Sales Estimates and Forecasts (2019-2030)
1.3 Peptide Cancer Vaccine Market by Pipeline
1.3.1 ITK-1
1.3.2 GRN-1201
1.3.3 TPIV200
1.3.4 TPIV110
1.3.5 UV1
1.3.6 Galinpepimut-S
1.3.7 TARP 27-35
1.3.8 HER-Vaxx
1.3.9 Vx-001
1.3.10 Others
1.4 Global Peptide Cancer Vaccine Market Size by Pipeline
1.4.1 Global Peptide Cancer Vaccine Market Size Overview by Pipeline (2019-2030)
1.4.2 Global Peptide Cancer Vaccine Historic Market Size Review by Pipeline (2019-2024)
1.4.3 Global Peptide Cancer Vaccine Forecasted Market Size by Pipeline (2025-2030)
1.5 Key Regions Market Size by Type
1.5.1 North America Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.2 Europe Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.3 Asia-Pacific Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.4 Latin America Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.5 Middle East and Africa Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
2 GLOBAL MARKET DYNAMICS
2.1 Peptide Cancer Vaccine Industry Trends
2.2 Peptide Cancer Vaccine Industry Drivers
2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
2.4 Peptide Cancer Vaccine Industry Restraints
3 MARKET COMPETITIVE LANDSCAPE BY COMPANY
3.1 Global Top Players by Peptide Cancer Vaccine Revenue (2019-2024)
3.2 Global Top Players by Peptide Cancer Vaccine Sales (2019-2024)
3.3 Global Top Players by Peptide Cancer Vaccine Price (2019-2024)
3.4 Global Peptide Cancer Vaccine Industry Company Ranking, 2022 VS 2023 VS 2024
3.5 Global Peptide Cancer Vaccine Key Company Manufacturing Sites & Headquarters
3.6 Global Peptide Cancer Vaccine Company, Product Type & Application
3.7 Global Peptide Cancer Vaccine Company Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023
3.8.3 2023 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier
4 PEPTIDE CANCER VACCINE REGIONAL STATUS AND OUTLOOK
4.1 Global Peptide Cancer Vaccine Market Size and CAGR by Region: 2019 VS 2023 VS 2030
4.2 Global Peptide Cancer Vaccine Historic Market Size by Region
4.2.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2019-2024)
4.2.2 Global Peptide Cancer Vaccine Sales in Value by Region (2019-2024)
4.2.3 Global Peptide Cancer Vaccine Sales (Volume & Value), Price and Gross Margin (2019-2024)
4.3 Global Peptide Cancer Vaccine Forecasted Market Size by Region
4.3.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2025-2030)
4.3.2 Global Peptide Cancer Vaccine Sales in Value by Region (2025-2030)
4.3.3 Global Peptide Cancer Vaccine Sales (Volume & Value), Price and Gross Margin (2025-2030)
5 PEPTIDE CANCER VACCINE BY APPLICATION
5.1 Peptide Cancer Vaccine Market by Application
5.1.1 Breast Cancer
5.1.2 Lung Cancer
5.1.3 Melanoma
5.1.4 Prostate Cancer
5.1.5 Others
5.2 Global Peptide Cancer Vaccine Market Size by Application
5.2.1 Global Peptide Cancer Vaccine Market Size Overview by Application (2019-2030)
5.2.2 Global Peptide Cancer Vaccine Historic Market Size Review by Application (2019-2024)
5.2.3 Global Peptide Cancer Vaccine Forecasted Market Size by Application (2025-2030)
5.3 Key Regions Market Size by Application
5.3.1 North America Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.2 Europe Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.3 Asia-Pacific Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.4 Latin America Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.5 Middle East and Africa Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
6 COMPANY PROFILES
6.1 Boston Biomedical
6.1.1 Boston Biomedical Comapny Information
6.1.2 Boston Biomedical Business Overview
6.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
6.1.5 Boston Biomedical Recent Developments
6.2 Ultimovacs
6.2.1 Ultimovacs Comapny Information
6.2.2 Ultimovacs Business Overview
6.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
6.2.5 Ultimovacs Recent Developments
6.3 BrightPath Biotherapeutics
6.3.1 BrightPath Biotherapeutics Comapny Information
6.3.2 BrightPath Biotherapeutics Business Overview
6.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
6.3.5 BrightPath Biotherapeutics Recent Developments
6.4 TapImmune
6.4.1 TapImmune Comapny Information
6.4.2 TapImmune Business Overview
6.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
6.4.5 TapImmune Recent Developments
6.5 Immatics
6.5.1 Immatics Comapny Information
6.5.2 Immatics Business Overview
6.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
6.5.5 Immatics Recent Developments
6.6 Sellas
6.6.1 Sellas Comapny Information
6.6.2 Sellas Business Overview
6.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
6.6.5 Sellas Recent Developments
6.7 Imugene
6.7.1 Imugene Comapny Information
6.7.2 Imugene Business Overview
6.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
6.7.5 Imugene Recent Developments
6.8 VAXON Biotech
6.8.1 VAXON Biotech Comapny Information
6.8.2 VAXON Biotech Business Overview
6.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
6.8.5 VAXON Biotech Recent Developments
6.9 Generex Biotechnology
6.9.1 Generex Biotechnology Comapny Information
6.9.2 Generex Biotechnology Business Overview
6.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
6.9.5 Generex Biotechnology Recent Developments
6.10 ISA Pharmaceuticals
6.10.1 ISA Pharmaceuticals Comapny Information
6.10.2 ISA Pharmaceuticals Business Overview
6.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
6.10.5 ISA Pharmaceuticals Recent Developments
6.11 OncoTherapy Science
6.11.1 OncoTherapy Science Comapny Information
6.11.2 OncoTherapy Science Business Overview
6.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
6.11.5 OncoTherapy Science Recent Developments
7 NORTH AMERICA BY COUNTRY
7.1 North America Peptide Cancer Vaccine Sales by Country
7.1.1 North America Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.1.2 North America Peptide Cancer Vaccine Sales by Country (2019-2024)
7.1.3 North America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
7.2 North America Peptide Cancer Vaccine Market Size by Country
7.2.1 North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2.2 North America Peptide Cancer Vaccine Market Size by Country (2019-2024)
7.2.3 North America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
8 EUROPE BY COUNTRY
8.1 Europe Peptide Cancer Vaccine Sales by Country
8.1.1 Europe Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.1.2 Europe Peptide Cancer Vaccine Sales by Country (2019-2024)
8.1.3 Europe Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
8.2 Europe Peptide Cancer Vaccine Market Size by Country
8.2.1 Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2.2 Europe Peptide Cancer Vaccine Market Size by Country (2019-2024)
8.2.3 Europe Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
9 ASIA-PACIFIC BY COUNTRY
9.1 Asia-Pacific Peptide Cancer Vaccine Sales by Country
9.1.1 Asia-Pacific Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.1.2 Asia-Pacific Peptide Cancer Vaccine Sales by Country (2019-2024)
9.1.3 Asia-Pacific Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
9.2 Asia-Pacific Peptide Cancer Vaccine Market Size by Country
9.2.1 Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2.2 Asia-Pacific Peptide Cancer Vaccine Market Size by Country (2019-2024)
9.2.3 Asia-Pacific Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
10 LATIN AMERICA BY COUNTRY
10.1 Latin America Peptide Cancer Vaccine Sales by Country
10.1.1 Latin America Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.1.2 Latin America Peptide Cancer Vaccine Sales by Country (2019-2024)
10.1.3 Latin America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
10.2 Latin America Peptide Cancer Vaccine Market Size by Country
10.2.1 Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2.2 Latin America Peptide Cancer Vaccine Market Size by Country (2019-2024)
10.2.3 Latin America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
11 MIDDLE EAST AND AFRICA BY COUNTRY
11.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country
11.1.1 Middle East and Africa Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.1.2 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2019-2024)
11.1.3 Middle East and Africa Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
11.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Country
11.2.1 Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Country (2019-2024)
11.2.3 Middle East and Africa Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
12 VALUE CHAIN AND SALES CHANNELS ANALYSIS
12.1 Peptide Cancer Vaccine Value Chain Analysis
12.1.1 Peptide Cancer Vaccine Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Peptide Cancer Vaccine Production Mode & Process
12.2 Peptide Cancer Vaccine Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Peptide Cancer Vaccine Distributors
12.2.3 Peptide Cancer Vaccine Customers
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
LIST OF TABLES
Table 1. Major Company of ITK-1
Table 2. Major Company of GRN-1201
Table 3. Major Company of TPIV200
Table 4. Major Company of TPIV110
Table 5. Major Company of UV1
Table 6. Major Company of Galinpepimut-S
Table 7. Major Company of TARP 27-35
Table 8. Major Company of HER-Vaxx
Table 9. Major Company of Vx-001
Table 10. Major Company of Others
Table 11. Global Peptide Cancer Vaccine Sales by Pipeline (2019 VS 2023 VS 2030) & (US$ Million)
Table 12. Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 13. Global Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline (2019-2024)
Table 14. Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 15. Global Peptide Cancer Vaccine Sales Market Share in Value by Pipeline (2019-2024)
Table 16. Global Peptide Cancer Vaccine Price by Pipeline (2019-2024) & (USD/Dose)
Table 17. Global Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 18. Global Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline (2025-2030)
Table 19. Global Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (US$ Million)
Table 20. Global Peptide Cancer Vaccine Sales Market Share in Value by Pipeline (2025-2030)
Table 21. Global Peptide Cancer Vaccine Price by Pipeline (2025-2030) & (USD/Dose)
Table 22. North America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 23. North America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 24. Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 25. Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 26. Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 27. Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 28. Latin America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 29. Latin America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 30. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 31. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 32. Peptide Cancer Vaccine Industry Trends
Table 33. Peptide Cancer Vaccine Industry Drivers
Table 34. Peptide Cancer Vaccine Industry Opportunities and Challenges
Table 35. Peptide Cancer Vaccine Industry Restraints
Table 36. Global Peptide Cancer Vaccine Sales Revenue by Company (US$ Million) & (2019-2024)
Table 37. Global Peptide Cancer Vaccine Revenue Market Share by Company (2019-2024)
Table 38. Global Peptide Cancer Vaccine Sales by Company (2019-2024) & (K Doses)
Table 39. Global Peptide Cancer Vaccine Sales Share by Company (2019-2024)
Table 40. Global Peptide Cancer Vaccine Market Price by Company (2019-2024) & (USD/Dose)
Table 41. Global Peptide Cancer Vaccine Industry Company Ranking, 2022 VS 2023 VS 2024
Table 42. Global Peptide Cancer Vaccine Key Company Manufacturing Sites & Headquarters
Table 43. Global Peptide Cancer Vaccine Company, Product Type & Application
Table 44. Global Peptide Cancer Vaccine Company Commercialization Time
Table 45. Global Company Market Concentration Ratio (CR5 and HHI)
Table 46. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 47. Global Peptide Cancer Vaccine Market Size Comparison by Region (US$ Million): 2019 VS 2023 VS 2030
Table 48. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (K Doses)
Table 49. Global Peptide Cancer Vaccine Sales Market Share in Volume by Region (2019-2024)
Table 50. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (US$ Million)
Table 51. Global Peptide Cancer Vaccine Sales Market Share in Value by Region (2019-2024)
Table 52. Global Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 53. Global Peptide Cancer Vaccine Sales by Region (2025-2030) & (K Doses)
Table 54. Global Peptide Cancer Vaccine Sales Market Share in Volume by Region (2025-2030)
Table 55. Global Peptide Cancer Vaccine Sales by Region (2025-2030) & (US$ Million)
Table 56. Global Peptide Cancer Vaccine Sales Market Share in Value by Region (2025-2030)
Table 57. Global Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2025-2030)
Table 58. Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030) & (US$ Million)
Table 59. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 60. Global Peptide Cancer Vaccine Sales Market Share in Volume by Application (2019-2024)
Table 61. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 62. Global Peptide Cancer Vaccine Sales Market Share in Value by Application (2019-2024)
Table 63. Global Peptide Cancer Vaccine Price by Application (2019-2024) & (USD/Dose)
Table 64. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 65. Global Peptide Cancer Vaccine Sales Market Share in Volume by Application (2025-2030)
Table 66. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (US$ Million)
Table 67. Global Peptide Cancer Vaccine Sales Market Share in Value by Application (2025-2030)
Table 68. Global Peptide Cancer Vaccine Price by Application (2025-2030) & (USD/Dose)
Table 69. North America Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 70. North America Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 71. Europe Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 72. Europe Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 73. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 74. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 75. Latin America Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 76. Latin America Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 77. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 78. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 79. Boston Biomedical Company Information
Table 80. Boston Biomedical Business Overview
Table 81. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 82. Boston Biomedical Peptide Cancer Vaccine Product Portfolio
Table 83. Boston Biomedical Recent Development
Table 84. Ultimovacs Company Information
Table 85. Ultimovacs Business Overview
Table 86. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 87. Ultimovacs Peptide Cancer Vaccine Product Portfolio
Table 88. Ultimovacs Recent Development
Table 89. BrightPath Biotherapeutics Company Information
Table 90. BrightPath Biotherapeutics Business Overview
Table 91. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 92. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
Table 93. BrightPath Biotherapeutics Recent Development
Table 94. TapImmune Company Information
Table 95. TapImmune Business Overview
Table 96. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 97. TapImmune Peptide Cancer Vaccine Product Portfolio
Table 98. TapImmune Recent Development
Table 99. Immatics Company Information
Table 100. Immatics Business Overview
Table 101. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 102. Immatics Peptide Cancer Vaccine Product Portfolio
Table 103. Immatics Recent Development
Table 104. Sellas Company Information
Table 105. Sellas Business Overview
Table 106. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 107. Sellas Peptide Cancer Vaccine Product Portfolio
Table 108. Sellas Recent Development
Table 109. Imugene Company Information
Table 110. Imugene Business Overview
Table 111. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 112. Imugene Peptide Cancer Vaccine Product Portfolio
Table 113. Imugene Recent Development
Table 114. VAXON Biotech Company Information
Table 115. VAXON Biotech Business Overview
Table 116. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 117. VAXON Biotech Peptide Cancer Vaccine Product Portfolio
Table 118. VAXON Biotech Recent Development
Table 119. Generex Biotechnology Company Information
Table 120. Generex Biotechnology Business Overview
Table 121. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 122. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
Table 123. Generex Biotechnology Recent Development
Table 124. ISA Pharmaceuticals Company Information
Table 125. ISA Pharmaceuticals Business Overview
Table 126. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 127. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
Table 128. ISA Pharmaceuticals Recent Development
Table 129. OncoTherapy Science Company Information
Table 130. OncoTherapy Science Business Overview
Table 131. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 132. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
Table 133. OncoTherapy Science Recent Development
Table 134. North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
Table 135. North America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 136. North America Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 137. North America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
Table 138. North America Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
Table 139. North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 140. North America Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 141. North America Peptide Cancer Vaccine Market Share by Country (2019-2024)
Table 142. North America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 143. North America Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
Table 144. Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
Table 145. Europe Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 146. Europe Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 147. Europe Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
Table 148. Europe Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
Table 149. Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 150. Europe Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 151. Europe Peptide Cancer Vaccine Market Share by Country (2019-2024)
Table 152. Europe Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 153. Europe Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
Table 154. Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
Table 155. Asia-Pacific Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 156. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 157. Asia-Pacific Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
Table 158. Asia-Pacific Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
Table 159. Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 160. Asia-Pacific Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 161. Asia-Pacific Peptide Cancer Vaccine Market Share by Country (2019-2024)
Table 162. Asia-Pacific Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 163. Asia-Pacific Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
Table 164. Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
Table 165. Latin America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 166. Latin America Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 167. Latin America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
Table 168. Latin America Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
Table 169. Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 170. Latin America Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 171. Latin America Peptide Cancer Vaccine Market Share by Country (2019-2024)
Table 172. Latin America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 173. Latin America Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
Table 174. Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
Table 175. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 176. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 177. Middle East and Africa Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
Table 178. Middle East and Africa Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
Table 179. Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 180. Middle East and Africa Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 181. Middle East and Africa Peptide Cancer Vaccine Market Share by Country (2019-2024)
Table 182. Middle East and Africa Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 183. Middle East and Africa Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
Table 184. Key Raw Materials
Table 185. Raw Materials Key Suppliers
Table 186. Peptide Cancer Vaccine Distributors List
Table 187. Peptide Cancer Vaccine Customers List
Table 188. Research Programs/Design for This Report
Table 189. Authors List of This Report
Table 190. Secondary Sources
Table 191. Primary Sources
Table 1. Major Company of ITK-1
Table 2. Major Company of GRN-1201
Table 3. Major Company of TPIV200
Table 4. Major Company of TPIV110
Table 5. Major Company of UV1
Table 6. Major Company of Galinpepimut-S
Table 7. Major Company of TARP 27-35
Table 8. Major Company of HER-Vaxx
Table 9. Major Company of Vx-001
Table 10. Major Company of Others
Table 11. Global Peptide Cancer Vaccine Sales by Pipeline (2019 VS 2023 VS 2030) & (US$ Million)
Table 12. Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 13. Global Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline (2019-2024)
Table 14. Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 15. Global Peptide Cancer Vaccine Sales Market Share in Value by Pipeline (2019-2024)
Table 16. Global Peptide Cancer Vaccine Price by Pipeline (2019-2024) & (USD/Dose)
Table 17. Global Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 18. Global Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline (2025-2030)
Table 19. Global Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (US$ Million)
Table 20. Global Peptide Cancer Vaccine Sales Market Share in Value by Pipeline (2025-2030)
Table 21. Global Peptide Cancer Vaccine Price by Pipeline (2025-2030) & (USD/Dose)
Table 22. North America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 23. North America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 24. Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 25. Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 26. Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 27. Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 28. Latin America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 29. Latin America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 30. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 31. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US$ Million)
Table 32. Peptide Cancer Vaccine Industry Trends
Table 33. Peptide Cancer Vaccine Industry Drivers
Table 34. Peptide Cancer Vaccine Industry Opportunities and Challenges
Table 35. Peptide Cancer Vaccine Industry Restraints
Table 36. Global Peptide Cancer Vaccine Sales Revenue by Company (US$ Million) & (2019-2024)
Table 37. Global Peptide Cancer Vaccine Revenue Market Share by Company (2019-2024)
Table 38. Global Peptide Cancer Vaccine Sales by Company (2019-2024) & (K Doses)
Table 39. Global Peptide Cancer Vaccine Sales Share by Company (2019-2024)
Table 40. Global Peptide Cancer Vaccine Market Price by Company (2019-2024) & (USD/Dose)
Table 41. Global Peptide Cancer Vaccine Industry Company Ranking, 2022 VS 2023 VS 2024
Table 42. Global Peptide Cancer Vaccine Key Company Manufacturing Sites & Headquarters
Table 43. Global Peptide Cancer Vaccine Company, Product Type & Application
Table 44. Global Peptide Cancer Vaccine Company Commercialization Time
Table 45. Global Company Market Concentration Ratio (CR5 and HHI)
Table 46. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 47. Global Peptide Cancer Vaccine Market Size Comparison by Region (US$ Million): 2019 VS 2023 VS 2030
Table 48. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (K Doses)
Table 49. Global Peptide Cancer Vaccine Sales Market Share in Volume by Region (2019-2024)
Table 50. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (US$ Million)
Table 51. Global Peptide Cancer Vaccine Sales Market Share in Value by Region (2019-2024)
Table 52. Global Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 53. Global Peptide Cancer Vaccine Sales by Region (2025-2030) & (K Doses)
Table 54. Global Peptide Cancer Vaccine Sales Market Share in Volume by Region (2025-2030)
Table 55. Global Peptide Cancer Vaccine Sales by Region (2025-2030) & (US$ Million)
Table 56. Global Peptide Cancer Vaccine Sales Market Share in Value by Region (2025-2030)
Table 57. Global Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2025-2030)
Table 58. Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030) & (US$ Million)
Table 59. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 60. Global Peptide Cancer Vaccine Sales Market Share in Volume by Application (2019-2024)
Table 61. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 62. Global Peptide Cancer Vaccine Sales Market Share in Value by Application (2019-2024)
Table 63. Global Peptide Cancer Vaccine Price by Application (2019-2024) & (USD/Dose)
Table 64. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 65. Global Peptide Cancer Vaccine Sales Market Share in Volume by Application (2025-2030)
Table 66. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (US$ Million)
Table 67. Global Peptide Cancer Vaccine Sales Market Share in Value by Application (2025-2030)
Table 68. Global Peptide Cancer Vaccine Price by Application (2025-2030) & (USD/Dose)
Table 69. North America Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 70. North America Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 71. Europe Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 72. Europe Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 73. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 74. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 75. Latin America Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 76. Latin America Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 77. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 78. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2019-2024) & (US$ Million)
Table 79. Boston Biomedical Company Information
Table 80. Boston Biomedical Business Overview
Table 81. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 82. Boston Biomedical Peptide Cancer Vaccine Product Portfolio
Table 83. Boston Biomedical Recent Development
Table 84. Ultimovacs Company Information
Table 85. Ultimovacs Business Overview
Table 86. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 87. Ultimovacs Peptide Cancer Vaccine Product Portfolio
Table 88. Ultimovacs Recent Development
Table 89. BrightPath Biotherapeutics Company Information
Table 90. BrightPath Biotherapeutics Business Overview
Table 91. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 92. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
Table 93. BrightPath Biotherapeutics Recent Development
Table 94. TapImmune Company Information
Table 95. TapImmune Business Overview
Table 96. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 97. TapImmune Peptide Cancer Vaccine Product Portfolio
Table 98. TapImmune Recent Development
Table 99. Immatics Company Information
Table 100. Immatics Business Overview
Table 101. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 102. Immatics Peptide Cancer Vaccine Product Portfolio
Table 103. Immatics Recent Development
Table 104. Sellas Company Information
Table 105. Sellas Business Overview
Table 106. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 107. Sellas Peptide Cancer Vaccine Product Portfolio
Table 108. Sellas Recent Development
Table 109. Imugene Company Information
Table 110. Imugene Business Overview
Table 111. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 112. Imugene Peptide Cancer Vaccine Product Portfolio
Table 113. Imugene Recent Development
Table 114. VAXON Biotech Company Information
Table 115. VAXON Biotech Business Overview
Table 116. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 117. VAXON Biotech Peptide Cancer Vaccine Product Portfolio
Table 118. VAXON Biotech Recent Development
Table 119. Generex Biotechnology Company Information
Table 120. Generex Biotechnology Business Overview
Table 121. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 122. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
Table 123. Generex Biotechnology Recent Development
Table 124. ISA Pharmaceuticals Company Information
Table 125. ISA Pharmaceuticals Business Overview
Table 126. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 127. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
Table 128. ISA Pharmaceuticals Recent Development
Table 129. OncoTherapy Science Company Information
Table 130. OncoTherapy Science Business Overview
Table 131. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 132. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
Table 133. OncoTherapy Science Recent Development
Table 134. North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
Table 135. North America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 136. North America Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 137. North America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
Table 138. North America Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
Table 139. North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 140. North America Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 141. North America Peptide Cancer Vaccine Market Share by Country (2019-2024)
Table 142. North America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 143. North America Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
Table 144. Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
Table 145. Europe Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 146. Europe Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 147. Europe Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
Table 148. Europe Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
Table 149. Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 150. Europe Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 151. Europe Peptide Cancer Vaccine Market Share by Country (2019-2024)
Table 152. Europe Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 153. Europe Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
Table 154. Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
Table 155. Asia-Pacific Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 156. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 157. Asia-Pacific Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
Table 158. Asia-Pacific Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
Table 159. Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 160. Asia-Pacific Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 161. Asia-Pacific Peptide Cancer Vaccine Market Share by Country (2019-2024)
Table 162. Asia-Pacific Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 163. Asia-Pacific Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
Table 164. Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
Table 165. Latin America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 166. Latin America Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 167. Latin America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
Table 168. Latin America Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
Table 169. Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 170. Latin America Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 171. Latin America Peptide Cancer Vaccine Market Share by Country (2019-2024)
Table 172. Latin America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 173. Latin America Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
Table 174. Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
Table 175. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 176. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
Table 177. Middle East and Africa Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
Table 178. Middle East and Africa Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
Table 179. Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 180. Middle East and Africa Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 181. Middle East and Africa Peptide Cancer Vaccine Market Share by Country (2019-2024)
Table 182. Middle East and Africa Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 183. Middle East and Africa Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
Table 184. Key Raw Materials
Table 185. Raw Materials Key Suppliers
Table 186. Peptide Cancer Vaccine Distributors List
Table 187. Peptide Cancer Vaccine Customers List
Table 188. Research Programs/Design for This Report
Table 189. Authors List of This Report
Table 190. Secondary Sources
Table 191. Primary Sources
LIST OF FIGURES
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Peptide Cancer Vaccine Market Size (2019-2030) & (US$ Million)
Figure 4. Global Peptide Cancer Vaccine Sales (2019-2030) & (K Doses)
Figure 5. Product Picture of ITK-1
Figure 6. Global ITK-1 Sales YoY Growth (2019-2030) & (K Doses)
Figure 7. Product Picture of GRN-1201
Figure 8. Global GRN-1201 Sales YoY Growth (2019-2030) & (K Doses)
Figure 9. Product Picture of TPIV200
Figure 10. Global TPIV200 Sales YoY Growth (2019-2030) & (K Doses)
Figure 11. Product Picture of TPIV110
Figure 12. Global TPIV110 Sales YoY Growth (2019-2030) & (K Doses)
Figure 13. Product Picture of UV1
Figure 14. Global UV1 Sales YoY Growth (2019-2030) & (K Doses)
Figure 15. Product Picture of Galinpepimut-S
Figure 16. Global Galinpepimut-S Sales YoY Growth (2019-2030) & (K Doses)
Figure 17. Product Picture of TARP 27-35
Figure 18. Global TARP 27-35 Sales YoY Growth (2019-2030) & (K Doses)
Figure 19. Product Picture of HER-Vaxx
Figure 20. Global HER-Vaxx Sales YoY Growth (2019-2030) & (K Doses)
Figure 21. Product Picture of Vx-001
Figure 22. Global Vx-001 Sales YoY Growth (2019-2030) & (K Doses)
Figure 23. Product Picture of Others
Figure 24. Global Others Sales YoY Growth (2019-2030) & (K Doses)
Figure 25. Global Peptide Cancer Vaccine Market Size Overview by Type (2019-2030) & (US$ Million)
Figure 26. Global Peptide Cancer Vaccine Market Share by Type 2023 VS 2030
Figure 27. North America Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
Figure 28. North America Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
Figure 29. Europe Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
Figure 30. Europe Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
Figure 31. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
Figure 32. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
Figure 33. Latin America Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
Figure 34. Latin America Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
Figure 35. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
Figure 36. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
Figure 37. Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023
Figure 38. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 39. Product Picture of Breast Cancer
Figure 40. Global Breast Cancer Sales YoY Growth (2019-2030) & (K Doses)
Figure 41. Product Picture of Lung Cancer
Figure 42. Global Lung Cancer Sales YoY Growth (2019-2030) & (K Doses)
Figure 43. Product Picture of Melanoma
Figure 44. Global Melanoma Sales YoY Growth (2019-2030) & (K Doses)
Figure 45. Product Picture of Prostate Cancer
Figure 46. Global Prostate Cancer Sales YoY Growth (2019-2030) & (K Doses)
Figure 47. Product Picture of Others
Figure 48. Global Others Sales YoY Growth (2019-2030) & (K Doses)
Figure 49. Global Peptide Cancer Vaccine Market Size Overview by Application (2019-2030) & (US$ Million)
Figure 50. Global Peptide Cancer Vaccine Market Share by Application 2023 VS 2030
Figure 51. North America Peptide Cancer Vaccine Sales Market Share in Volume by Application in 2023
Figure 52. North America Peptide Cancer Vaccine Sales Market Share in Value by Application in 2023
Figure 53. Europe
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Peptide Cancer Vaccine Market Size (2019-2030) & (US$ Million)
Figure 4. Global Peptide Cancer Vaccine Sales (2019-2030) & (K Doses)
Figure 5. Product Picture of ITK-1
Figure 6. Global ITK-1 Sales YoY Growth (2019-2030) & (K Doses)
Figure 7. Product Picture of GRN-1201
Figure 8. Global GRN-1201 Sales YoY Growth (2019-2030) & (K Doses)
Figure 9. Product Picture of TPIV200
Figure 10. Global TPIV200 Sales YoY Growth (2019-2030) & (K Doses)
Figure 11. Product Picture of TPIV110
Figure 12. Global TPIV110 Sales YoY Growth (2019-2030) & (K Doses)
Figure 13. Product Picture of UV1
Figure 14. Global UV1 Sales YoY Growth (2019-2030) & (K Doses)
Figure 15. Product Picture of Galinpepimut-S
Figure 16. Global Galinpepimut-S Sales YoY Growth (2019-2030) & (K Doses)
Figure 17. Product Picture of TARP 27-35
Figure 18. Global TARP 27-35 Sales YoY Growth (2019-2030) & (K Doses)
Figure 19. Product Picture of HER-Vaxx
Figure 20. Global HER-Vaxx Sales YoY Growth (2019-2030) & (K Doses)
Figure 21. Product Picture of Vx-001
Figure 22. Global Vx-001 Sales YoY Growth (2019-2030) & (K Doses)
Figure 23. Product Picture of Others
Figure 24. Global Others Sales YoY Growth (2019-2030) & (K Doses)
Figure 25. Global Peptide Cancer Vaccine Market Size Overview by Type (2019-2030) & (US$ Million)
Figure 26. Global Peptide Cancer Vaccine Market Share by Type 2023 VS 2030
Figure 27. North America Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
Figure 28. North America Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
Figure 29. Europe Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
Figure 30. Europe Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
Figure 31. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
Figure 32. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
Figure 33. Latin America Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
Figure 34. Latin America Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
Figure 35. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
Figure 36. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
Figure 37. Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023
Figure 38. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 39. Product Picture of Breast Cancer
Figure 40. Global Breast Cancer Sales YoY Growth (2019-2030) & (K Doses)
Figure 41. Product Picture of Lung Cancer
Figure 42. Global Lung Cancer Sales YoY Growth (2019-2030) & (K Doses)
Figure 43. Product Picture of Melanoma
Figure 44. Global Melanoma Sales YoY Growth (2019-2030) & (K Doses)
Figure 45. Product Picture of Prostate Cancer
Figure 46. Global Prostate Cancer Sales YoY Growth (2019-2030) & (K Doses)
Figure 47. Product Picture of Others
Figure 48. Global Others Sales YoY Growth (2019-2030) & (K Doses)
Figure 49. Global Peptide Cancer Vaccine Market Size Overview by Application (2019-2030) & (US$ Million)
Figure 50. Global Peptide Cancer Vaccine Market Share by Application 2023 VS 2030
Figure 51. North America Peptide Cancer Vaccine Sales Market Share in Volume by Application in 2023
Figure 52. North America Peptide Cancer Vaccine Sales Market Share in Value by Application in 2023
Figure 53. Europe
